Tech Transfer eNews Blog

Hoth Therapeutics licenses COVID-19 therapeutic from VCU


By Jesse Schwartz
Published: June 3rd, 2020

Biotech company Hoth Therapeutics has licensed a technology from Virginia Commonwealth University (VCU) that prevents spike protein binding, which could effectively treat COVID-19 by halting its replication.

Developed by VCU professor Michael H. Peters, the novel peptide therapeutic is designed to slow the transmission of the virus by binding to the SARS-Cov-2 spike protein and mimicking its attachment to a lung cell surface receptor known as ACE2. This receptor is essentially the virus’ gateway into the lung. The new therapeutic helps block the spike protein from accessing it, thus limiting transmission.

Peters developed the technology, in part, using powerful supercomputers as part of the COVID-19 High Performance Computing Consortium, a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.

“Computer modeling of SARS-CoV-2’s spike protein is an important step in finding ways to prevent the virus from binding to ACE2 receptors and allowing the virus to replicate,” says Ivelina Metcheva, senior executive director of VCU’s Innovation Gateway. “We are very excited to assist Dr. Peter’s collaboration with Hoth Therapeutics to develop potentially life-saving therapy for COVID-19.”

Hoth CEO Robb Knie comments, “My team and Board have continued to see remarkable technologies that could have potential breakthroughs in the fight against COVID-19. Dr. Peters and his team have been working diligently on analyzing data surrounding the theory of SARS-CoV-2’s spike protein, its potential effect on COVID-19 and developing a therapeutic that would be effective in limiting transmission of the virus.”

Source: PR Newswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment